Hemodynamics Monitoring During Lower Body Negative Pressure (LBNP) Induced Controlled Hypovolemia
LBPN
2 other identifiers
observational
120
1 country
1
Brief Summary
To monitor the changes in central and peripheral monitors/waveforms during gradual hypovolemia induced by lower body negative pressure in healthy volunteers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 15, 2017
CompletedFirst Submitted
Initial submission to the registry
June 13, 2018
CompletedFirst Posted
Study publicly available on registry
July 19, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2027
January 20, 2026
January 1, 2026
9.1 years
June 13, 2018
January 15, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Identify the most robust site for monitoring hypovolemia utilizing pulse oximeter waveforms.
Data will be summarized using mean (SD) for normally distributed data, median (interquartile range) for non-normal data. linear regression method will be used to model the changes of our dependent variable from baseline during blood loss.
2 years
Secondary Outcomes (1)
Examine the relationship between central hemodynamic changes (cardiac output) with changes in respiratory variability of PPG waveforms collected from different sites during hypovolemia and fluid resuscitation
2 years
Interventions
We will be monitoring the changes in central and peripheral monitors/waveforms during gradual hypovolemia induced by lower body negative pressure in healthy volunteers.
Eligibility Criteria
Healthy volunteers aged 20-45 with no history of heart disease, diabetes, or hypertension. Pregnant women will be excluded.
You may qualify if:
- \* Healthy volunteers aged 20-45 with
You may not qualify if:
- Pregnant women
- Under 20 years of age
- Subjects with coronary artery disease, diabetes, epilepsy and hypertension
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Yale Universitylead
Study Sites (1)
John B. Pierce Laboratory
New Haven, Connecticut, 06520, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Aymen Alian, MD
Yale University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 13, 2018
First Posted
July 19, 2018
Study Start
November 15, 2017
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
January 1, 2027
Last Updated
January 20, 2026
Record last verified: 2026-01